Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00412412 · ClinicalTrials.gov registry record · Phase 1
CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00412412 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 34 participants.
The verdict
NCT00412412, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to study the drug CNF2024 as a single agent or in combination with trastuzumab in patients with advanced breast cancer and to: * find the highest dose of the drug CNF2024 as a single agent or in combination with trastuzumab that can be given safely * measure levels of CNF2024 as a single agent or in combination with trastuzumab in blood * determine if CNF2024 as a single agent or in combination with trastuzumab can stop breast cancer cells from growing
Interventions
- DRUG CNF2024
- DRUG CNF2024 + trastuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00412412
The ClinicalTrials.gov registry entry for NCT00412412 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CNF2024 is the first listed.
NCT00412412 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00412412 about?
NCT00412412 is a clinical study titled "CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study". The goal of this clinical research study is to study the drug CNF2024 as a single agent or in combination with trastuzumab in patients with advanced breast cancer and to: * find the highest dose of the drug CNF2024 as a single agent or in combination with trastuzumab that can be given safely * meas...
What is the current status of trial NCT00412412?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2007-12. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00412412?
The interventions under investigation include: CNF2024 (DRUG), CNF2024 + trastuzumab (DRUG).
Who is sponsoring clinical trial NCT00412412?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.